All Articles

With girl-focused charities receiving less than 2% of donations, Atlanta's male executives are stepping up to close a critical investment gap. Here's why.

Tiziana Life Sciences has dosed the final patient in a key trial for its nasal MS drug, foralumab. With data imminent, this could be a breakthrough for an untreatable form of the disease.

The age of SEO is over. A new report reveals AI now curates what we buy based on a brand's total internet presence, not just its ads. Welcome to the Recommendation Era.

With its stock lagging despite strong sales, Insulet brings on a proven value-creator. Can the 'Mazelsky Playbook' accelerate growth and fend off rivals?

Analyst firm QKS Group names Compass Plus a leader, but the real story is how its modern, API-first architecture is rewiring card payments for banks.

Beyond the music, the 2026 CCMA Awards reveal a powerful synergy between city branding, artist entrepreneurship, and integrated media strategy. A new blueprint?

A new player is spending big to bring multi-gig internet to Chicagoland. But in a crowded market, Ezee Fiber's real test isn't speed—it's strategy.

By offering free Starlink Wi-Fi, Alaska Air Group isn't just upgrading a service; it's weaponizing connectivity to win loyalty and challenge rivals.

The lender's 10% yield attracts income investors, but a tight payout ratio and market shifts raise questions about its long-term sustainability.

A new contract goes beyond equipment, revealing a strategic blueprint for Angola's energy sector, local growth, and the future of ultra-deepwater operations.

Lightbridge Corp. hits a critical milestone at Idaho National Lab, moving its advanced nuclear fuel from theory to tangible data. What does this signal mean?

The sudden death of veteran counsel E. Forrest Jones Jr. leaves a void at Ramaco Resources, testing its leadership amid a high-stakes pivot to critical minerals.

FlightHub is expanding from flights to a full-service travel platform. But can its new hotel booking service truly challenge giants like Expedia and Booking.com?

A landmark publication in The Lancet unveils AC01, a novel oral drug that safely improves heart function, offering a beacon of hope for millions with heart failure.

With late-stage veterans on board, MRM Health isn't just advancing a drug; it's building the strategic architecture for microbiome's leap from lab to market.

By fast-tracking its novel oral drug for atopic dermatitis, Kymera isn't just advancing a treatment—it's validating a new class of medicine.

Verano's upcoming Q2 report is a key indicator for the cannabis sector. We look at the strategic moves, from stock splits to rescheduling, setting the stage.

China's data center giant GDS secures a massive war chest and reshuffles its board, signaling an aggressive push to dominate the AI infrastructure boom.

A landmark acquisition is set to 4x IQSTEL's net income. But the real story is its pivot from a low-margin carrier to a high-margin digital services powerhouse.